Neutropenia News and Research

RSS
Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils, the most important type of white blood cell, in the blood.

Further Reading

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

17 Jun 2011
CTI announces positive results from Phase I-II pixantrone combination study against INHL

CTI announces positive results from Phase I-II pixantrone combination study against INHL

17 Jun 2011
Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

Astellas, Ambit Biosciences announce interim results from AC220 Phase 2 trial against AML

14 Jun 2011
Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

Millennium reports results from two MLN9708 ongoing Phase I studies on multiple myeloma

13 Jun 2011
Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium reports results from two VELCADE based combination studies against multiple myeloma

8 Jun 2011
Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

Topline results from 4SC vidofludimus Phase IIb trial against rheumatoid arthritis

8 Jun 2011
Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

Telik initiates Telintra Phase 2 trial in Revlimid refractory or resistant, del 5q MDS

8 Jun 2011
ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

7 Jun 2011
Unique clinical trial addresses important questions about treating AIDS-related cancers

Unique clinical trial addresses important questions about treating AIDS-related cancers

7 Jun 2011
Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

Dacogen Phase III study results on acute myeloid leukemia presented at ASCO 2011

7 Jun 2011
Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

7 Jun 2011
Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

Teva's lipegfilgrastim-pegfilgrastim comparative Phase III study in breast cancer meets primary endpoint

7 Jun 2011
Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

6 Jun 2011
Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO

Positive interim results from CTI's OPAXIO-TMZ phase II trial on malignant brain tumors presented at ASCO

6 Jun 2011
Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint

Bayer's radium-223 chloride Phase III trial in CRPC, bone metastases meet primary endpoint

6 Jun 2011
YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis

YM reports updated interim results from CYT387 Phase I/II study on myelofibrosis

4 Jun 2011
Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

2 Jun 2011
FDA approves SUTENT for treatment of pancreatic NET

FDA approves SUTENT for treatment of pancreatic NET

21 May 2011
FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

FDA approves Sutent for patients with progressive neuroendocrine cancerous tumors in pancreas

21 May 2011
Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

20 May 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback